For a normal person, the loops, kinks, and folds in the single strand of RNA that makes up the coronavirus genome might look like a bowl of spaghetti. However, to researchers like Amanda Hargrove, who is a chemistry professor at Duke University, the complex shaped RNA had untapped therapeutic potential in the fight against COVID-19. Hargrove and her colleagues had identified chemical compounds that could latch onto these 3D structures and block the virus's ability to replicate.
The findings of this study were published in the 'Science Advances Journal'.
"These are the first molecules with an antiviral activity that target the virus's RNA specifically, so it's a totally new mechanism in that sense," Hargrove said.
Even more than 18 months into the pandemic, that's good news. We have vaccines to prevent COVID-19, but effective, easy-to-administer drugs to help people survive and recover once they've been infected remained limited.
The virus is receding in some parts of the world, but cases are still surging in others where vaccines are in short supply. And even in regions with easy access to vaccines, COVID-19 vaccine hesitancy meant many of the world's eight billion people remained vulnerable to infection.
To infect your cells, the coronavirus must break in, deliver its genetic instructions in the form of RNA, and hijack the body's molecular machinery to build new copies of it. The infected cell became a virus factory, reading the 30,000 nucleotides "letters" of the virus's genetic code and churning out the proteins the virus needed to replicate and spread.
Most antivirals -- including remdesivir, molnupiravir and Paxlovid, the only antiviral drugs for COVID-19 that had been FDA-approved or are in line for approval -- worked by binding to these proteins. But Hargrove and colleagues took a different approach. They identified the first molecules that aimed at the viral genome itself -- and not just the linear sequence of A's, C's, G's and U's, but the complex three-dimensional structures the RNA strand folded into.
When the first terrifying hints of the pandemic started to make headlines, the team including Hargrove, Blanton Tolbert from Case Western Reserve University and Gary Brewer and Mei-Ling Li from Rutgers were already investigating potential drug candidates to fight another RNA virus -- Enterovirus 71, a common cause of hand, foot and mouth disease in children.
They had identified a class of small molecules called amiloride that can bind to hairpin-like folds in the virus's genetic material and throw a wrench in the virus's replication.
To see if the same compounds could work against coronaviruses too, first, they tested 23 amiloride-based molecules against another, far less deadly coronavirus responsible for many common colds. They identified three compounds that, when added to infected monkey cells, reduced the amount of virus within 24 hours of infection without causing collateral damage to their host cells. They also showed greater effects at higher doses. The researchers got similar results when they tested the molecules on cells infected with SARS-CoV-2, the virus that causes COVID-19.
Further work showed that the molecules stopped the virus from building up by binding to a site in the first 800 letters of the viral genome. Most of this stretch of RNA doesn't code for proteins itself but drives their production.
The region folded in on itself to form multiple bulges and hairpin-like structures. Using computer modelling and a technique called nuclear magnetic resonance spectroscopy, the researchers were able to analyze these 3D RNA structures and pinpoint where the chemical compounds were binding.
The researchers are still trying to figure out exactly how these compounds stopped the virus from multiplying, once they're bound to its genome.
When it comes to using RNA as a drug target, Hargrove said that the field is still in its early stages. Part of the reason is that RNA structures are unstable. They bounce around a lot more than their protein counterparts, which made it hard to design molecules that can interact with them in specific ways.
"The binding pocket that you're looking for may not even be present most of the time," Hargrove said.
What's more, 85 per cent of the RNA in an infected cell don't belong to the virus, but to the ribosomes -- cellular particles made of RNA and protein -- of its human host.
"There's a sea of competition," Hargrove said.
But Hargrove is hopeful. The first small-molecule drug that has worked by binding to non-ribosomal RNA directly, rather than proteins, was just approved by the FDA last August, to treat people with a devastating disease called spinal muscular atrophy.
"So while there are lots of challenges, it's not impossible," Hargrove said.
The researchers have a patent pending on their method. They wanted to modify the compounds to make them more potent, and then test them in mice "to see if this could be a viable drug candidate," Hargrove said.
This isn't the first time that coronaviruses have caused an outbreak, and it likely won't be the last, the researchers said. In the last two decades, the same family of viruses was responsible for SARS, which emerged in China and spread to more than two dozen countries in 2002, and MERS, first reported in Saudi Arabia in 2012.
The researchers determined that the loops and bulges of RNA they identified have remained essentially unchanged by evolution across related coronaviruses in bats, rats and humans, including the ones that caused the SARS and MERS outbreaks. That means their method might be able to fight more than just SARS-CoV-2, the virus that causes COVID-19.
Clearly, more antivirals would be valuable weapons to have, so when the next pandemic hits we'll be better prepared. Having more drugs on hand would have another benefit: fighting resistance. Viruses mutate over time. Being able to combine drugs with different mechanisms of action would make it less likely that the virus could develop resistance to all of them simultaneously and become impossible to treat, Hargrove said.
"This is a new way to think about antivirals for RNA viruses," Hargrove said.